Septerna Inc (SEPN) Stock Score, Valuation & Financial Research
Septerna Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 36/100.
Quick answer for SEPN
Septerna Inc currently has a Wall Street Score of 36/100. The stored market price is $38.44. Its financial score is 50/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Septerna Inc does
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metaboli
SEPN financial snapshot
- Wall Street Score:
- 36/100
- Current price:
- $38.44
- Market capitalization:
- $1.73B
- Revenue:
- $72.3M
- Net income:
- $-36.0M
- Free cash flow:
- $109.7M
- Cash:
- $71.6M
- Total debt:
- $23.1M
- EPS:
- -1.10
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.6%.
- Free cash flow is $109.7M, showing positive cash generation.
- The balance sheet shows $71.6M of cash versus $23.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SEPN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.